Ratings by Craig-Hallum (Robin Garner)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/12/2024 | Avadel Pharmaceuticals | AVDL | Maintain | Buy (N/A) |
|
Details | ||
| 6/30/2023 | Avadel Pharmaceuticals | AVDL | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2023 | Avadel Pharmaceuticals | AVDL | Maintain | Buy (N/A) |
|
Details | ||
| 7/28/2022 | Avadel Pharmaceuticals | AVDL | New Coverage | Buy (N/A) |
4.55 (17.82) |
291.65% | Details | |
| 3/18/2022 | Cue Biopharma | CUE | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2022 | Cue Biopharma | CUE | New Coverage | Buy (N/A) |
11.35 (1.41) |
-87.58% | Details | |
| 10/20/2021 | Landos Biopharma | LABP | New Coverage | Buy (N/A) |
14.92 (22.49) |
50.74% | Details | |
| 8/2/2021 | Forma Therapeutics | FMTX | New Coverage | Buy (N/A) |
22.89 (20.01) |
-12.58% | Details | |
| 5/25/2021 | Strongbridge Biopharma | SBBP | Downgrade | Hold (Buy) |
2.70 (2.00) |
-25.93% | Details | |
| 4/21/2021 | Fennec Pharmaceuticals Inc. | FENC | New Coverage | Buy (N/A) |
6.22 (9.16) |
47.27% | Details | |
| 3/26/2021 | Processa Pharmaceuticals | PCSA | Maintain | Buy (N/A) |
|
Details | ||
| 12/1/2020 | Strongbridge Biopharma | SBBP | New Coverage | Buy (N/A) |
2.77 (2.00) |
-27.8% | Details |
